Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in : a multicenter, randomized phase IIb studyKRAS: a multicenter, randomized phase IIb study wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles